Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | NetApp | Celestica | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The FY2026 10-K shows a real, durable lock but not an unassailable one. On the durable side: "Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings", and the same filing's income statement shows the company holding a gross margin near 71% across all three reported years - $4,433M on $6,268M in FY2024, $4,613M on $6,572M in FY2025 and $4,899M on $6,925M in FY2026 - while revenue grew from $6,268M to $6,925M and income from operations widened from 19% to 24% of net revenues. Holding that margin through the memory-cost shock the same filing discloses is the commercial evidence the lock is worth something. On the limiting side, the filing says competition "is intense", that in public cloud "customers may choose native cloud services that are consumed as operating expenses", and that "New competitors or alliances among existing competitors could emerge and quickly gain significant market share" - and IDC's 1Q26 external-storage tracker (Blocks & Files, 2026-06-16, cited on the AFF/ASA product row below) ranks NetApp second behind Dell, not first. | narrow The FY2025 10-K shows a real but bounded edge. On the durable side, Celestica is increasingly engaged as an ODM: its HPS business co-designs (JDM) or fully designs the platforms it builds, it states 'We have hardware and software patents that are integral to our HPS business' and that 'our increased R&D activities have resulted in the growth of our dependence on our patent portfolio', and HPS reached 41% of total revenue in 2025 (from 21% in 2023) at a margin profile the filing says is higher than traditional EMS work. On the limiting side, the same filing concedes 'Some of our competitors have greater scale and provide a broader range of services than we provide', the master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', work is won 'on a program-by-program basis', and the top 10 customers were 79% of 2025 revenue with three customers individually at 32%, 14% and 12%. An advantage that must be re-won each program against greater-scale rivals, for a handful of buyers who can in-source, is narrow rather than wide. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | switching costs The FY2026 10-K makes the source of the advantage explicit and it is the cost of leaving the data-management layer, not a network or a patent estate. The same ONTAP software runs the on-premises arrays and the cloud services ("Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings"), and the AFF family "allows customers to connect to clouds for more data services, data tiering, caching, and disaster recovery". A customer's volume layout, snapshot and replication workflow and operating tools therefore carry from the array into Azure, AWS and Google rather than being abandoned at the cloud boundary — the filing describes NetApp as "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers", so the usual moment of escape is instead the moment the relationship renews. | switching costs Cost scale is explicitly not the source: the 10-K states competitors have greater scale and a broader service range. What does bind a customer is the design-in. Within HPS, Celestica 'design[s] and manufacture[s] products, either as customized solutions, white box solutions or under Joint Design and Manufacturing (JDM) engagements', holds 'hardware and software patents that are integral to our HPS business', and delivers 'complete platform solutions... integration and orchestration of various technologies into rack-scale designs'. The filing adds that 'a majority of these supply agreements also require the customer to purchase unused inventory that we have purchased to fulfill that customer's forecasted manufacturing demand', a contractual cost of walking away mid-program. Moving a qualified, jointly designed rack-scale platform to another ODM means requalifying a design Celestica partly owns, which is friction the commodity assembly work does not carry. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader IDC's 1Q26 external enterprise storage systems tracker, as reported by Blocks & Files on 2026-06-16 (cited in full on the AFF/ASA product row below), ranks NetApp second worldwide behind Dell and ahead of Everpure, Huawei and HPE, attributing the placing to "its growing all-flash business and cloud-integrated data management". Second of five ranked vendors, in a market whose leader is someone else, is a shared front rank rather than an owned one - and the distinct claim NetApp makes in the FY2026 10-K is positional rather than volumetric: being "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers". | at parity The 10-K claims no share leadership. It states plainly that 'Some of our competitors have greater scale and provide a broader range of services than we provide', and lists Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus in EMS plus Quanta, Wiwynn and Accton in ODM. Its stated competitive advantage is execution quality, not position: 'our track record in advanced manufacturing capabilities, design and engineering, quality, delivery, managing complexity and responsiveness'. It is also winning: CCS revenue grew 42% to $9.19 billion and total revenue reached $12.39 billion in FY2025. Competing on comparable terms with a field it neither leads nor trails is parity. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate It holds price rather than raising it. On the figures filed with the FY2026 10-K, gross margin was 70.7% of revenue in FY2024 ($4,433M on $6,268M), 70.2% in FY2025 ($4,613M on $6,572M) and 70.7% in FY2026 ($4,899M on $6,925M) - flat across three years in which revenue grew from $6,268M to $6,925M - and it held that level while absorbing a component-cost shock. It is no stronger than that because the filing's own risk factor lists "competitive pricing, customer price sensitivity" and "pricing and discounting pressures" among the drivers of gross margin, and discloses that the company "experienced inflationary pressure and supply chain constraints beginning in the second half of fiscal 2026, resulting in increased costs for memory and other components, which have affected our gross margins" - a cost shock it is absorbing rather than fully passing on. | weak The filing describes price as contested by contract, not set by Celestica: master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', 'Some of these agreements require us to provide specific price reductions to our customers over the term of the contracts', and the Item 1A risk factor 'We operate in an industry comprised of numerous competitors and aggressive pricing dynamics' says competitors may be 'willing to, or able to make sales or provide services at lower margins than we do'. The site's fundamentals show gross margin at 12.06% in FY2025, up from 8.96% in FY2022, 9.47% in FY2023 and 10.72% in FY2024 — improving, but still low double digits, and the filing attributes the higher margin to mix (HPS is 'higher margin profile than our traditional EMS businesses' and went from 21% to 41% of revenue over the same span) rather than to raising prices. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | NetApp sells storage hardware but the asset is ONTAP, the data-management software that has run its arrays for over three decades and now also runs inside the three largest public clouds as a first-party service. The FY2026 10-K organises the company into two segments, Hybrid Cloud (AFF and ASA all-flash arrays, AFX for AI workloads, FAS hybrid-flash, E/EF-Series, StorageGRID object storage) and Public Cloud (Azure NetApp Files, Amazon FSx for NetApp ONTAP, Google Cloud NetApp Volumes, Cloud Volumes ONTAP), and states that both rest on the same ONTAP software. That is the whole argument: an enterprise that has standardised its snapshots, replication and multiprotocol access on ONTAP carries those habits with it when it moves workloads to a hyperscaler, and NetApp is paid on both sides of the move. The evidence that the lock has commercial value is the margin's steadiness: across the three years the FY2026 10-K reports, gross margin sat at 70.7%, 70.2% and 70.7% of revenue ($4,433M on $6,268M, $4,613M on $6,572M, $4,899M on $6,925M) while revenue grew, and the filing's own percentage-of-revenue table shows no mix shift doing that work - product and services held near 46% and 54% of revenue throughout. The limits are equally in the filing. NetApp is second, not first: IDC's 1Q26 tracker puts it behind Dell in external enterprise storage, and the 10-K's competition section concedes that cloud providers are simultaneously partners and rivals, that consumption models "may reduce overall demand for our traditional on-premises offerings sold through a capital expenditure (capex) model", and that alternative architectures "may reduce or eliminate demand for some of our offerings". Component exposure is real too: the filing discloses "inflationary pressure and supply chain constraints beginning in the second half of fiscal 2026, resulting in increased costs for memory and other components, which have affected our gross margins", and names NAND among the components whose supply can tighten. This is a durable second place built on software stickiness, not a structural monopoly. | Celestica is a contract design and manufacturing company that has been pulled up the value chain by the AI data-center build-out. Its CCS segment, which builds networking switches, optical systems, data center racks, servers and storage for hyperscalers and other cloud and AI service providers, grew 42% to $9.19 billion in 2025, and Communications alone went from 33% of revenue in 2023 to 57% in 2025. The part of that business with a defensible position is HPS, where Celestica is the designer rather than the assembler: HPS revenue rose 81% in 2025 to 41% of the total, carries a higher margin than traditional EMS work, and rests on a patent portfolio the filing calls integral to the business. That design-in position is what separates it from pure build-to-print capacity. What caps the moat is the customer side of the ledger. The 10-K describes an industry where 'aggressive pricing is a common business dynamic', where master supply agreements guarantee neither volume nor price and some of them 'require us to provide specific price reductions to our customers over the term of the contracts', and where the company bids program by program against Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus on the EMS side and Quanta, Wiwynn and Accton on the ODM side, plus Arista and Cisco where a customer might buy an off-the-shelf switch instead. Revenue concentration has tightened as the AI mix grew, from 64% of revenue in the top 10 customers in 2023 to 79% in 2025, with a single customer at 32%. The company also notes its HPS offerings can compete with a customer's own hardware, which may 'negatively impact our relationship with, or result in a loss of business from, such customers'. So the profile is a genuine but program-scoped advantage, held by a company whose fortunes turn on a few buyers' capital plans. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | NetApp sits between the memory supply and the enterprise data centre. Upstream, the FY2026 10-K says "Third-party component costs make up a significant portion of our product costs" and singles out NAND as hard to manage "if supplies of certain components, including NAND, become limited relative to demand". Downstream, the hyperscalers are channel, partner and rival at once: the filing states "We both partner with and compete against cloud service providers through our cloud-based software and services offerings", while Azure NetApp Files, Amazon FSx for NetApp ONTAP and Google Cloud NetApp Volumes are delivered as those clouds' own natively embedded services. Distribution is a mix of direct sales and "an ecosystem of partners, including the leading cloud providers". | Celestica sits between component suppliers and the hyperscale buyer, and owns the design only in part of that span. It 'procure[s] substantially all of our materials and components on behalf of our customers pursuant to individual purchase orders that are generally short-term in nature', then designs, assembles, integrates at rack scale and tests the switches, optical systems, servers, storage and data-center racks that cloud, AI and enterprise customers deploy. In ATS it is a pure EMS contractor that does 'not generally collaborate with ATS customers on the design of the solutions we manufacture'; in HPS it is the designer of record or a joint designer. The economics follow that split: the segment where it holds design IP is the one with the higher margin profile. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |